Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Clin Gastroenterol ; 51(1): 56-62, 2017 01.
Article in English | MEDLINE | ID: mdl-27182647

ABSTRACT

INTRODUCTION: Domperidone, a peripheral D2 dopamine receptor antagonist, has efficacy for treatment of nausea, dyspepsia, and gastroparesis. Domperidone prolongs the QT interval (QTc), and may cause life-threatening arrhythmias. METHODS: Electronic medical records for all patients receiving domperidone in the NorthShore University HealthSystem from January 1, 2008 to December 1, 2013 were reviewed. All concomitant medications were noted. The coadministration of QT-interacting medications was determined. Electrocardiogram (EKG) evaluation before and during domperidone therapy was noted. A query of the FDA Adverse Event Reporting System (FAERS) database was also performed. Individual reports from the FAERS Web site from January 2008 to June 2014 were downloaded and analyzed. The database was queried for all reports of adverse events with domperidone. Coadministration of QT-interacting medications was noted. Cardiac events that potentially were related to prolongation of the QTc were examined. RESULTS: In total, 108 of 155 patients (69.7%) were coprescribed QT-interacting drugs along with domperidone. Fifty-nine of 155 patients (38.1%) underwent a baseline EKG and 9 (15.3%) had prolongation of the QTc at initiation. Forty patients (25.8%) had a follow-up EKG and 13 (32.5%) had prolongation of the QTc. All 13 were coprescribed QT-interacting medications. On the FAERS, 221 nonfatal cardiac events were reported in domperidone patients; of these, 162 (73.3%) occurred in patients receiving QT-interacting medications. Coprescription occurred in 53 of 151 deaths (35.1%) and in 16 of 61 cardiac arrests (26.2%). CONCLUSIONS: Coprescribing of QT-prolonging medications and inconsistent EKG monitoring occur in patients receiving domperidone, placing these patients at risk for arrhythmias.


Subject(s)
Antiemetics/adverse effects , Domperidone/adverse effects , Drug Interactions , Gastrointestinal Diseases/drug therapy , Long QT Syndrome/chemically induced , Adult , Adverse Drug Reaction Reporting Systems , Aged , Aged, 80 and over , Antiemetics/administration & dosage , Domperidone/administration & dosage , Dyspepsia/drug therapy , Female , Gastroparesis/drug therapy , Humans , Male , Middle Aged , Nausea/drug therapy , Product Surveillance, Postmarketing , Retrospective Studies , Young Adult
2.
Inflamm Bowel Dis ; 22(5): 1095-100, 2016 May.
Article in English | MEDLINE | ID: mdl-26914437

ABSTRACT

BACKGROUND: Inflammatory bowel disease (IBD) is associated with an increased risk of acute pancreatitis (AP). Our group examined differences in length of stay and costs for patients with IBD hospitalized for AP and the general population. METHODS: Using the National Inpatient Sample, we examined all admissions during 2005 to 2011 with a primary diagnosis of AP and codiagnosis of IBD. Continuous variables were reported as mean ± SD and compared between IBD and controls. To compare the outcomes of interest, we conducted a 1:3 propensity score matching using a greedy algorithm based on age, gender, race, number of comorbidities, procedures, insurance, income quartiles, hospital bed size, hospital location, and teaching status. Statistical analyses were performed on SAS 9.3 (Cary, NC). RESULTS: There were 4291 hospitalizations of patients with IBD and AP over the 7-year period and 379,627 hospitalizations of patients without IBD and with AP. More patients with Crohn's disease developed AP than patients with ulcerative colitis (2145 versus 1219). The length of stay and costs for patients with AP and IBD were significantly higher than controls (5.7 days versus 4.9 days, P < 0.0001 and $29,724.89 versus $27,916.76, P < 0.0001). The percentage of patients with alcohol abuse was lower in patients with IBD than that of controls (11.8% versus 21.7%, P < 0.0001). However, the percentage of patients with IBD who were drug abusers was higher than controls (5.8% versus 4.3%, P < 0.0005). CONCLUSIONS: Our study suggests that a codiagnosis of Crohn's disease or ulcerative colitis incurs a greater economic burden in patients with AP.


Subject(s)
Hospital Costs/statistics & numerical data , Hospitalization/economics , Inflammatory Bowel Diseases/economics , Inpatients/statistics & numerical data , Pancreatitis/economics , Case-Control Studies , Follow-Up Studies , Humans , Inflammatory Bowel Diseases/therapy , Pancreatitis/therapy , Prognosis , Retrospective Studies , Survival Rate
3.
World J Gastroenterol ; 22(48): 10601-10608, 2016 Dec 28.
Article in English | MEDLINE | ID: mdl-28082812

ABSTRACT

AIM: To clarify the association of malignancy with mesenteric panniculitis-like changes on computed tomography (CT). METHODS: All abdominal CT scans performed at NorthShore University HealthSystem showing mesenteric panniculitis from January 2005 to August 2010 were identified in the Radnet (RadNet Corporation, Los Angeles, CA) database. Patients with a new or known diagnosis of a malignancy were included for this analysis. Longitudinal clinical histories were obtained from electronic medical records. RESULTS: In total, 147794 abdominal CT scans were performed during the study period. Three hundred and fifty-nine patients had mesenteric panniculitis (MP)-like abnormalities on their abdominal CT. Of these patients, 81 patients (22.6%) had a known history of cancer at the time of their CT scan. Nineteen (5.3%) had a new diagnosis of cancer in concurrence with their CT, but the majority of these (14/19, 74%) were undergoing CT as part of a malignancy evaluation. Lymphomas were the most common cancers associated with MP-like findings on CT (36 cases, 36%), with follicular lymphoma being the most frequent subtype (17/36). A variety of solid tumors, most commonly prostate (7) and renal cell cancers (6) also were seen. CT follow up was obtained in 56 patients. Findings in the mesentery were unchanged in 45 (80%), worsened in 6 (11%), and improved in 5 patients (9%). Positron emission tomography (PET) scans performed in 44 patients only showed a positive uptake in the mesenteric mass in 2 patients (5%). CONCLUSION: A new diagnosis of cancer is uncommon in patients with CT findings suggestive of MP. MP-like mesenteric abnormalities on CT generally remain stable in patients with associated malignancies. PET scanning is not recommended in the evaluation of patients with mesenteric panniculitis-like findings on CT.


Subject(s)
Carcinoma, Renal Cell/diagnostic imaging , Kidney Neoplasms/diagnostic imaging , Lymphoma/diagnostic imaging , Panniculitis, Peritoneal/diagnostic imaging , Peritoneal Neoplasms/diagnostic imaging , Prostatic Neoplasms/diagnostic imaging , Abdomen/diagnostic imaging , Biopsy , Carcinoma, Renal Cell/pathology , Databases, Factual , Diagnosis, Differential , Early Detection of Cancer/methods , Electronic Health Records , Humans , Kidney Neoplasms/pathology , Longitudinal Studies , Lymphoma/epidemiology , Male , Mesentery/pathology , Panniculitis, Peritoneal/epidemiology , Peritoneal Neoplasms/epidemiology , Peritoneal Neoplasms/secondary , Positron-Emission Tomography , Prostatic Neoplasms/pathology , Retrospective Studies , Tomography, X-Ray Computed , United States/epidemiology
4.
ACG Case Rep J ; 3(1): 39-41, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26504876

ABSTRACT

We report the first case of acute Vibrio cholerae infection with computed tomography (CT) changes consistent with mesenteric panniculitis (MP). A 78-year-old Indian man returned from overseas travel with progressively severe nausea, vomiting, abdominal pain, and watery diarrhea. His stool tested positive twice for Vibrio cholerae. CT revealed prominent lymph nodes and a hazy mesentery consistent with MP. Antibiotic treatment resulted in complete resolution of MP on follow-up CT 8 months later. In the setting of Vibrio cholerae infection, the CT finding of MP appears to be the result of a immunologically mediated reactive inflammatory disorder of the mesentery.

7.
Inflamm Bowel Dis ; 20(12): 2493-502, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25230166

ABSTRACT

Nonsteroidal anti-inflammatory drugs (NSAIDs) produce significant gastrointestinal (GI) adverse events. Laboratory and clinical studies suggest that NSAIDs have the potential to trigger the onset or relapse of inflammatory bowel disease. In this review, the currently available information on the mechanism of action of NSAID injury of the GI tract and the pathophysiology of GI effects of NSAIDs, including immune dysregulation will be assessed. A detailed description of NSAID effects on individual GI organs will be discussed. This is followed by a MEDLINE review of clinical literature on the relationship between NSAID ingestion and the development and worsening of inflammatory bowel disease.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Gastrointestinal Tract/drug effects , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/physiopathology , Humans , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL
...